NCT03931291 - APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 16, 2019

Primary Completion Date

August 27, 2021

Study Completion Date

January 14, 2022

Conditions

Acute Myeloid Leukemia or Myelodysplastic Syndromes

Interventions

DRUG

APR-246

APR-246 will be administered on Days 1-4, with azacitidine on Days 1-5, of every 28 day cycle. Patients may receive a maximum of 12 cycles.

Trial Locations (7)

Memorial Sloan Kettering Cancer Center, New York

Johns Hopkins, Sidney Kimmel Comprehensive Cancer Center, Baltimore

H. Lee Moffitt Cancer Center & Research Institute, Tampa

Vanderbilt Ingram Cancer Center, Nashville

Fred Hutchinson Cancer Center, Seattle

Massachusetts General Hospital, Boston

Dana Farber Cancer Institute, Boston